Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity

View ORCID ProfileSonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, View ORCID ProfileRolando Ochoa-Azze, View ORCID ProfileYanet Climent-Ruiz, View ORCID ProfileCarlos Alberto González-Delgado, Beatriz Paredes-Moreno, View ORCID ProfileCarmen Valenzuela-Silva, View ORCID ProfileLaura Rodríguez-Noda, View ORCID ProfileRocmira Perez-Nicado, View ORCID ProfileRaúl González-Mugica, View ORCID ProfileMarisel Martínez-Pérez, View ORCID ProfileBelinda Sánchez-Ramírez, View ORCID ProfileTays Hernández-García, View ORCID ProfileAlina Díaz-Machado, View ORCID ProfileMaura Tamayo-Rodríguez, View ORCID ProfileAlis Martín-Trujillo, View ORCID ProfileJorman Rubino-Moreno, View ORCID ProfileAnamary Suárez-Batista, View ORCID ProfileMarta Dubed-Echevarría, View ORCID ProfileMaría Teresa Pérez-Guevara, View ORCID ProfileMayté Amoroto-Roig, View ORCID ProfileYanet Chappi-Estévez, View ORCID ProfileGretchen Bergado-Báez, View ORCID ProfileFranciscary Pi-Estopiñán, Guang-Wu Chen, View ORCID ProfileYuri Valdés-Balbín, View ORCID ProfileDagmar García-Rivera, View ORCID ProfileVicente Vérez-Bencomo
doi: https://doi.org/10.1101/2021.10.04.21264522
Sonia Pérez-Rodríguez
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sonia Pérez-Rodríguez
Meiby de la Caridad Rodríguez-González
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolando Ochoa-Azze
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rolando Ochoa-Azze
  • For correspondence: ochoa{at}finlay.edu.cu
Yanet Climent-Ruiz
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yanet Climent-Ruiz
Carlos Alberto González-Delgado
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos Alberto González-Delgado
Beatriz Paredes-Moreno
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Valenzuela-Silva
3Institute of Cybernetics, Mathematics and Physics, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carmen Valenzuela-Silva
Laura Rodríguez-Noda
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura Rodríguez-Noda
Rocmira Perez-Nicado
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rocmira Perez-Nicado
Raúl González-Mugica
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raúl González-Mugica
Marisel Martínez-Pérez
2Finlay Vaccine Institute, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marisel Martínez-Pérez
Belinda Sánchez-Ramírez
4Centre of Molecular Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Belinda Sánchez-Ramírez
Tays Hernández-García
4Centre of Molecular Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tays Hernández-García
Alina Díaz-Machado
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alina Díaz-Machado
Maura Tamayo-Rodríguez
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maura Tamayo-Rodríguez
Alis Martín-Trujillo
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alis Martín-Trujillo
Jorman Rubino-Moreno
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorman Rubino-Moreno
Anamary Suárez-Batista
5Research Center of Civil Defense, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anamary Suárez-Batista
Marta Dubed-Echevarría
5Research Center of Civil Defense, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marta Dubed-Echevarría
María Teresa Pérez-Guevara
5Research Center of Civil Defense, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for María Teresa Pérez-Guevara
Mayté Amoroto-Roig
6National Coordinating Centre of Clinical Trials
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mayté Amoroto-Roig
Yanet Chappi-Estévez
6National Coordinating Centre of Clinical Trials
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yanet Chappi-Estévez
Gretchen Bergado-Báez
4Centre of Molecular Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gretchen Bergado-Báez
Franciscary Pi-Estopiñán
4Centre of Molecular Immunology, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Franciscary Pi-Estopiñán
Guang-Wu Chen
7Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuri Valdés-Balbín
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuri Valdés-Balbín
Dagmar García-Rivera
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dagmar García-Rivera
Vicente Vérez-Bencomo
1National Centre of Toxicology (CENATOX), Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vicente Vérez-Bencomo
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the target for many COVID-19 vaccines. Here we report results for phase 1 clinical trial of two COVID-19 vaccine candidates based on recombinant dimeric RBD (d-RBD).

Methods We performed a randomized, double-blind, phase I clinical trial in the National Centre of Toxicology in Havana. Sixty Cuban volunteers aged 19-59 years were randomized into three groups (20 subjects each): 1) FINLAY-FR-1 (50 mcg d-RBD plus outer membrane vesicles from N. meningitidis); 2) FINLAY-FR-1A-50 mcg d-RBD (three doses); 3) FINLAY-FR-1A-25 mcg d-RDB (three doses). The FINLAY-FR-1 group was randomly divided to receive a third dose of the same vaccine candidate (homologous schedule) or of FINLAY-FR-1A-50 (heterologous schedule). The primary outcomes were safety and reactogenicity. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following each vaccination was evaluated using live-virus neutralization test, anti-RBD IgG ELISA and in-vitro neutralization test of RBD:hACE2 interaction.

Results Most adverse events were of mild intensity (63.5%), solicited (58.8%), and local (61.8%); 69.4% with causal association with vaccination. Serious adverse events were not found. The FINLAY-FR-1 group reported more adverse events than the other two groups. After the third dose, anti-RBD seroconversion was 100%, 94.4% and 90% for the FINLAY-FR-1, FINLAY-FR-1A-50 and FINLAY-FR-1A-25 respectively. The in-vitro inhibition of RBD:hACE2 interaction increased after the second dose in all formulations. The geometric mean neutralizing titres after the third dose rose significantly in the group vaccinated with FINLAY-FR-1 with respect to the other formulations and the COVID-19 Convalescent Serum Panel. No differences were found between FINLAY-FR-1 homologous or heterologous schedules.

Conclusions Vaccine candidates were safe and immunogenic, and induced live-virus neutralizing antibodies against SARS-CoV-2. The highest values were obtained when outer membrane vesicles were used as adjuvant.

Trial registry https://rpcec.sld.cu/en/trials/RPCEC00000338-En

Competing Interest Statement

Some authors are researchers of Finlay Vaccine Institute, and the Centre of Molecular Immunology, the institutions that manufacture the vaccines.

Clinical Trial

https://rpcec.sld.cu/en/trials/RPCEC00000338-En

Clinical Protocols

https://rpcec.sld.cu/en/trials/RPCEC00000338-En)

Funding Statement

Partial funding for this study was received from Fondo de Ciencia e Innovacion (FONCI) of Cuba Ministry of Science, Technology and the Environment (Project-2020-20).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Cuban Ministry of Public Health (MINSAP), the Independent Ethics Committee (IEC) for Studies on Human Subjects, at CENATOX and the Cuban National Regulatory Agency (Centre for State Control of Medicines and Medical Devices, CECMED), approved the trial and the procedures (CECMED, Authorization date: 13/10/2020, Reference number: 05.013.20BA. It was conducted according to the Declaration of Helsinki and Good Clinical Practice. An Independent Data Monitoring Committee (IDMC) analysed safety, reactogenicity, and immunogenicity data. During recruitment, investigators provided potential participants with extensive oral and written information. The decision to participate in the study was completely voluntary. Written informed consent was obtained from all volunteers. During the study, the IEC and IDMC assessed the trial risk-benefit ratio and assured the rights, health and privacy of volunteers, including information confidentiality.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵δ Joint first authors

Data Availability

Information is available at the Cuban Public Registry of Clinical Trials, included in WHO International Clinical Trials Registry Platform (Soberana 01A, RPCEC https://rpcec.sld.cu/en/trials/RPCEC00000338-En). Other supporting clinical data and documents, including immunological individual data, will be available after publication of this article through direct request to: ochoa{at}finlay.edu.cu or: vicente.verez{at}finlay.edu.cu.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity
Sonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Carlos Alberto González-Delgado, Beatriz Paredes-Moreno, Carmen Valenzuela-Silva, Laura Rodríguez-Noda, Rocmira Perez-Nicado, Raúl González-Mugica, Marisel Martínez-Pérez, Belinda Sánchez-Ramírez, Tays Hernández-García, Alina Díaz-Machado, Maura Tamayo-Rodríguez, Alis Martín-Trujillo, Jorman Rubino-Moreno, Anamary Suárez-Batista, Marta Dubed-Echevarría, María Teresa Pérez-Guevara, Mayté Amoroto-Roig, Yanet Chappi-Estévez, Gretchen Bergado-Báez, Franciscary Pi-Estopiñán, Guang-Wu Chen, Yuri Valdés-Balbín, Dagmar García-Rivera, Vicente Vérez-Bencomo
medRxiv 2021.10.04.21264522; doi: https://doi.org/10.1101/2021.10.04.21264522
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity
Sonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Carlos Alberto González-Delgado, Beatriz Paredes-Moreno, Carmen Valenzuela-Silva, Laura Rodríguez-Noda, Rocmira Perez-Nicado, Raúl González-Mugica, Marisel Martínez-Pérez, Belinda Sánchez-Ramírez, Tays Hernández-García, Alina Díaz-Machado, Maura Tamayo-Rodríguez, Alis Martín-Trujillo, Jorman Rubino-Moreno, Anamary Suárez-Batista, Marta Dubed-Echevarría, María Teresa Pérez-Guevara, Mayté Amoroto-Roig, Yanet Chappi-Estévez, Gretchen Bergado-Báez, Franciscary Pi-Estopiñán, Guang-Wu Chen, Yuri Valdés-Balbín, Dagmar García-Rivera, Vicente Vérez-Bencomo
medRxiv 2021.10.04.21264522; doi: https://doi.org/10.1101/2021.10.04.21264522

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (755)
  • Anesthesia (221)
  • Cardiovascular Medicine (3288)
  • Dentistry and Oral Medicine (364)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13360)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5147)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3264)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (429)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14622)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (127)
  • Nephrology (522)
  • Neurology (4919)
  • Nursing (262)
  • Nutrition (727)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2519)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4205)
  • Public and Global Health (7500)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1011)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)